POLB and cancer: These polβ cancer-associated variants possess aberrant activity in vitro such as diminished fidelity, stemming from reduced discrimination against incorrect nucleotides, leading to mutator phenotypes (Y265C and E288K), slower rate of dRP lyase (L22P) or polymerase (S229L) activity and a complete lack of gap filling activity (E295K) (17–30).